Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million (USD 35.1 million) in China, underscoring its commitment to the market despite challenges posed by the COVID-19 pandemic. The announcement was made during the 34th International Business Leaders’ Advisory Council for the Mayor of Shanghai.
Recent Investments
Roche remains confident in China’s long-term growth potential, having invested over RMB 1.4 billion (USD 196.7 million) in the country over the past three years. In 2019, the company invested RMB 863 million (USD 121.2 million) to upgrade its research and development (R&D) center in Zhangjiang into its Shanghai Innovation Center. In 2021, Roche further committed RMB 300 million (USD 42.1 million) to establish the China Accelerator, aimed at fostering innovation and collaboration in the healthcare sector.
Future Outlook
Roche’s continued investment in China highlights its strategic focus on expanding its presence and capabilities in the region. By enhancing its R&D infrastructure and innovation ecosystem, Roche aims to drive forward scientific advancements and improve patient outcomes in the country.-Fineline Info & Tech
